(AOF) – OSE Immunotherapeutics announces a cash position of 18.7 million euros as of December 31, 2023, to which will be added $48 million expected under the agreement with AbbVie and the CIR estimated at 5.8 million euros, which will strengthen financial visibility until 2026. The biotech specialist in immuno-oncology and immuno-inflammation posts a consolidated net loss of 23.22 million euros compared to 17.76 million in 2022. It has recorded an operational loss of 23 million euros in 2023 compared to 18.4 billion euros a year ago.
Current operating expenses amounted to 25.2 million euros (compared to 36.6 million euros in 2022), including 74% dedicated to R&D. R&D expenses amounted to 17.2 million euros compared to 26.9 million euros in 2022.
“Today, the company has a broad and diversified portfolio of five clinical assets, three research platforms and three partnerships, all with potential key milestones in 2024,” underlines CEO Nicolas Poirier. “We have reached important milestones in 2023 and everything that has been put in place during the year will make it possible, in the coming months, to accelerate the major priorities on our products in the clinic and preclinical, in immuno-oncology and in inflammation “.
© 2024 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends using the buttons below.
